Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | HTR7 | P34969 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528252 | 0.90 | MAPT (0.86) | MAPTLMNANPSR1HTR1AHTR7 | |
| SCHEMBL4383007 | 0.90 | MAPT (0.58) | MAPTLMNANPSR1HTR1AHTR7 | |
| SCHEMBL3090713 | 0.90 | POLB (0.77) | MAPTLMNANPSR1HTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4376006 | 0.89 | MAPT (0.57) | MAPTLMNANPSR1HTR1AHTR7 | |
| SCHEMBL27786793 | 0.85 | MAPT (0.78) | MAPTLMNANPSR1HTR1AHTR7 | |
| SCHEMBL4382306 | 0.83 | MAPT (0.55) | MAPTLMNANPSR1HTR1AHTR7 | |
| SCHEMBL3070168 | 0.82 | HTR1A (0.69) | MAPTLMNAHTR1AHTR7MEN1 | |
| SCHEMBL7169669 | 0.82 | ALDH1A1 (0.63) | MAPTKMT2AALDH1A1GAANPC1 | |
| SCHEMBL28135156 | 0.82 | MAPT (0.78) | MAPTLMNANPSR1HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL4377741 | 0.82 | MAPT (0.54) | MAPTLMNANPSR1HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | MAPT 1435/4885LMNA 4786/4885NPSR1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.